XML 101 R83.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]    
Derivative [Line Items]    
Asset derivatives $ 0 $ 0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]    
Derivative [Line Items]    
Liability derivatives 0 0
Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]    
Derivative [Line Items]    
Asset derivatives [1] 0 8
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]    
Derivative [Line Items]    
Asset derivatives 71 38
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]    
Derivative [Line Items]    
Liability derivatives (24) (39)
Not Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]    
Derivative [Line Items]    
Asset derivatives [1] $ 0 $ 0
[1] On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. The agreement was terminated in the first quarter of 2024 and resulted in cash proceeds of $16 million.